Keyphrases
5-fluorouracil (5-FU)
53%
Adenocarcinoma of the Esophagogastric Junction
37%
Advanced Esophageal Cancer
14%
Advanced Gastric Cancer
21%
Advanced or Metastatic
20%
Cancer Patients
13%
Capecitabine
29%
Cetuximab
23%
Chemotherapy
46%
Cisplatin
38%
Docetaxel
33%
Elderly Patients
15%
Esophageal Cancer
15%
Esophagogastric Adenocarcinoma
31%
Fluoropyrimidine
25%
Fluorouracil
25%
Gastric Cancer
67%
Gastroesophageal Adenocarcinoma
21%
Gastroesophageal Cancer
14%
Gastroesophageal Junction
16%
Gastroesophageal Junction Cancer
34%
Histological Response
21%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Immune Checkpoint Inhibitors
15%
In Cancer
13%
Leucovorin
26%
Locally Advanced
39%
Metastatic Colorectal Cancer (mCRC)
16%
Metastatic Gastric Cancer
24%
Monotherapy
13%
Neoadjuvant
18%
Neoadjuvant Chemotherapy
22%
Overall Survival
33%
Oxaliplatin
42%
Paclitaxel
18%
Pembrolizumab
13%
Phase II Study
14%
Phase II Trial
45%
Programmed Death-ligand 1 (PD-L1)
21%
Progression-free Survival
17%
Quality of Life
17%
Ramucirumab
31%
Randomized Phase II Trial
24%
Second-line Treatment
19%
Standard of Care
18%
Taxanes
14%
Trastuzumab
32%
Treatment Options
15%
Treatment Strategy
15%
Tumor
38%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
88%
Adenocarcinoma
84%
Adverse Event
17%
Biological Marker
19%
Capecitabine
21%
Cetuximab
18%
Chemotherapy
100%
Chemotherapy Induced Nausea and Vomiting
7%
Cisplatin
37%
Clinical Trial
9%
Disease
25%
Disease Free Survival
11%
Docetaxel
34%
Epidermal Growth Factor Receptor
12%
Epidermal Growth Factor Receptor 2
14%
Esophageal Squamous Cell Carcinoma
7%
Esophagus Cancer
15%
Esophagus Carcinoma
7%
Esophagus Tumor
7%
First-Line Chemotherapy
8%
Fluoropyrimidine
28%
Fluorouracil
52%
Folinic Acid
37%
Gamma Urogastrone
13%
Immunotherapy
16%
Ipilimumab
7%
Irinotecan
10%
Malignant Neoplasm
66%
Metastasis
8%
Metastatic Colorectal Cancer
8%
Monotherapy
10%
Neoplasm
55%
Nivolumab
12%
Overall Survival
39%
Oxaliplatin
37%
Paclitaxel
17%
Panitumumab
7%
Pembrolizumab
11%
Phase II Trials
33%
Placebo
10%
Polyethylene Terephthalate
10%
Progression Free Survival
16%
Ramucirumab
30%
Skin Toxicity
7%
Squamous Cell Carcinoma
11%
Stomach Adenocarcinoma
10%
Stomach Tumor
7%
Survival Rate
9%
Taxane
13%
Trastuzumab
26%
Medicine and Dentistry
Abdominal Cancer
62%
Adenocarcinoma
82%
Adverse Event
8%
Arm
21%
Biological Marker
20%
Carcinoma
10%
Chemoradiotherapy
15%
Chemotherapy
79%
Cisplatin
16%
Clinical Oncology
8%
Clinical Trial
15%
Disease
27%
Disease Free Survival
9%
Docetaxel
23%
Elderly Patient
14%
Esophageal Cancer
17%
Fluoropyrimidine
20%
Fluorouracil
20%
FOLFOX
12%
Folinic Acid
18%
Gastroesophageal Junction
44%
Immunity
14%
Immunotherapy
27%
Malignant Neoplasm
81%
Metastatic Carcinoma
11%
Metastatic Colorectal Cancer
12%
Monotherapy
9%
Neoadjuvant Chemotherapy
19%
Neoplasm
55%
Nivolumab
11%
Overall Survival
29%
Oxaliplatin
24%
Paclitaxel
9%
Pembrolizumab
14%
Phase II Trials
12%
Placebo
9%
Polyethylene Terephthalate
23%
Positron Emission Tomography
12%
Programmed Cell Death
9%
Programmed Death-Ligand 1
10%
Progression Free Survival
13%
Quality of Life
13%
Ramucirumab
13%
Stomach Adenocarcinoma
9%
Stomach Carcinoma
10%
Surgery
21%
Survival Rate
9%
Systemic Therapy
16%
Targeted Therapy
14%
Trastuzumab
22%
